NCT03600714View on ClinicalTrials.gov

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

February 5, 2020

Study Completion Date

August 11, 2020

Conditions
Liver DiseaseHepatitis D
Interventions
DRUG

Peg-interferon lambda

Peg-interferon Lambda is a covalent conjugate of human recombinant non- pegylated interferon (IFN) lambda and a 20-kDa linear pegylated (PEG) chain.

DRUG

Lonafarnib

Oral prenylation inhibitor

DRUG

Ritonavir

Booster of lonafarnib action

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT03600714 - Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon | Biotech Hunter | Biotech Hunter